Coronavirus disease 2019-induced hypercoagulability and its clinical implications

Area of Science:

• Immunology
• Pathology
• Cardiology

Background:

• Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, which infects host cells via the ACE2 receptor.
• Viral replication triggers an immune response, involving lymphocytes, cytokines, and reactive oxygen species, leading to endothelial cell damage.

Purpose of the Study:

• To elucidate the mechanisms of endothelial damage and prothrombotic state in COVID-19.
• To highlight the role of complement activation and clot formation in pulmonary capillaries.
• To emphasize the necessity of anticoagulation therapy.

Main Methods:

• Review of the pathophysiological cascade initiated by SARS-CoV-2 infection.
• Analysis of immune mediators, complement system activation, and endothelial cell interactions.
• Examination of the prothrombotic environment and its clinical markers like D-dimer.

Main Results:

• SARS-CoV-2 infection leads to immune-mediated endothelial damage.
• Complement activation (C5a, MAC) exacerbates endothelial injury.
• Inhibition of clot lysis and promotion of adhesion molecules create a prothrombotic state in pulmonary capillaries, evidenced by elevated D-dimer.

Conclusions:

• COVID-19 induces significant endothelial dysfunction and a prothrombotic environment.
• Anticoagulation protocols are essential for managing thrombotic complications in COVID-19.
• Early intervention is critical to prevent pulmonary circulation compromise and right ventricle dysfunction.